Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14370523 | 0.90 | OPRM1 (0.42) | OPRM1OPRD1CA12CA1CA2 | |
| SCHEMBL432561 | 0.84 | OPRM1 (0.59) | OPRM1OPRD1CA12CA1CA2 | |
| SCHEMBL1558011 | 0.83 | ALDH1A1 (0.38) | OPRM1NPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL31147216 | 0.82 | POLB (0.38) | OPRM1OPRD1OPRL1MEN1KMT2A | |
| SCHEMBL3410998 | 0.81 | HSD11B1 (0.39) | OPRM1OPRD1CA12CA1CA2 | |
| SCHEMBL4439942 | 0.81 | SCD (0.40) | OPRM1OPRL1KMT2A | |
| SCHEMBL9248206 | 0.81 | KMT2A (0.41) | OPRM1OPRD1MEN1KMT2ANPC1 | |
| SCHEMBL11059742 | 0.81 | MAOB (0.48) | OPRM1RAB9ASMN1; SMN2POLBGAA | |
| SCHEMBL5382735 | 0.80 | OPRM1 (0.40) | OPRM1OPRD1CA12CA1CA2 | |
| SCHEMBL626037 | 0.79 | OPRM1 (0.51) | OPRM1OPRD1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289837-A1 | MITOCHONDRIOTROPIC HETEROARYL BENZAMIDE POTASSIUM CHANNEL KV1.3 INHIBITORS | UNIV LJUBLJANI (SI) | 2025-09-18 | — | — | US | disclosed |
| EP-4511125-A1 | MITOCHONDRIOTROPIC BENZAMIDE POTASSIUM CHANNEL K1.3 INHIBITORS | Univerza V Ljubljani (SI) | 2025-02-26 | — | — | EP | disclosed |
| WO-2023203185-A1 | MITOCHONDRIOTROPIC BENZAMIDE POTASSIUM CHANNEL K V1.3 INHIBITORS | UNIVERZA V LJUBLJANI (SI) | 2023-10-26 | — | — | WO | disclosed |
| EP-2502907-B1 | Substituted 4-aminocyclohexane derivatives | GRUENENTHAL GMBH (DE) | 2018-08-29 | — | — | EP | disclosed |
| EP-2518052-B1 | Substituted 4-aminocyclohexane derivatives | GRUENENTHAL GMBH (DE) | 2017-12-20 | — | — | EP | disclosed |
| US-9580386-B2 | Substituted 4-aminocyclohexane derivatives | GRÜNENTHAL (DE) | 2017-02-28 | — | — | US | disclosed |
| EP-2943495-B1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2016-12-28 | — | — | EP | disclosed |
| US-9403767-B2 | Substituted 4-aminocyclohexane derivatives | GRUENENTHAL GMBH (DE) | 2016-08-02 | — | — | US | disclosed |
| EP-2943495-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | Savira Pharmaceuticals GmbH (AT) | 2015-11-18 | — | — | EP | disclosed |
| US-9045486-B2 | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | SAVIRA PHARMACEUTICALS GMBH (AT) | 2015-06-02 | — | — | US | disclosed |
| EP-2041142-A1 | SPIROCYCLIC AZAINDOLE DERIVATIVES | Grünenthal GmbH (DE) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008009416-A1 | SPIROCYCLIC AZAINDOLE DERIVATIVES | Grünenthal GmbH (DE) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008009415-A2 | 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1- AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM | Grünenthal GmbH (DE) | 2008-01-24 | — | — | WO | disclosed |
| US-20070299080-A1 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | AMGEN INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299080-A1 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | AMGEN INC. | 2007-12-27 | — | — | US | disclosed |
| WO-2007145835-A2 | BENZAMIDE DERIVATIVES AS MODULATORS OF 11BETA-HSD1 FOR TREATING DIABETES AND OBESITY | AMGEN INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289837-A1 | MITOCHONDRIOTROPIC HETEROARYL BENZAMIDE POTASSIUM CHANNEL KV1.3 INHIBITORS | KCNJ2, KCNN3, KCNA3 | OPRM1 4705/4885OPRD1 4073/4885CA12 4451/4885 |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNN3, KCNQ5 | OPRM1 2782/4885OPRD1 1635/4885CA12 4882/4885 |
| US-20070299080-A1 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | HSD3B1, HSD17B1, HSD3B2 | OPRM1 2425/4885OPRD1 270/4885CA12 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.